- Home
- BRAG vs CHRS Comparison
BRAG vs CHRS Comparison
Compare BRAG & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRAG
- CHRS
- Stock Information
- Founded
- BRAG 2018
- CHRS 2010
- Country
- BRAG Canada
- CHRS United States
- Employees
- BRAG N/A
- CHRS N/A
- Industry
- BRAG Office Equipment/Supplies/Services
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRAG Technology
- CHRS Health Care
- Exchange
- BRAG Nasdaq
- CHRS Nasdaq
- Market Cap
- BRAG 117.8M
- CHRS 112.5M
- IPO Year
- BRAG N/A
- CHRS 2014
- Fundamental
- Price
- BRAG $4.29
- CHRS $0.97
- Analyst Decision
- BRAG Strong Buy
- CHRS Strong Buy
- Analyst Count
- BRAG 3
- CHRS 4
- Target Price
- BRAG $7.33
- CHRS $5.26
- AVG Volume (30 Days)
- BRAG 38.4K
- CHRS 1.7M
- Earning Date
- BRAG 05-15-2025
- CHRS 05-12-2025
- Dividend Yield
- BRAG N/A
- CHRS N/A
- EPS Growth
- BRAG N/A
- CHRS N/A
- EPS
- BRAG N/A
- CHRS 0.25
- Revenue
- BRAG $105,602,029.00
- CHRS $266,959,999.00
- Revenue This Year
- BRAG $17.94
- CHRS N/A
- Revenue Next Year
- BRAG $9.56
- CHRS $9.02
- P/E Ratio
- BRAG N/A
- CHRS $3.90
- Revenue Growth
- BRAG 9.07
- CHRS 3.78
- 52 Week Low
- BRAG $2.86
- CHRS $0.66
- 52 Week High
- BRAG $6.70
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- BRAG 56.12
- CHRS 48.50
- Support Level
- BRAG $3.92
- CHRS $0.92
- Resistance Level
- BRAG $4.59
- CHRS $1.12
- Average True Range (ATR)
- BRAG 0.19
- CHRS 0.07
- MACD
- BRAG 0.07
- CHRS -0.01
- Stochastic Oscillator
- BRAG 69.10
- CHRS 21.28
About BRAG Bragg Gaming Group Inc.
Bragg Gaming Group Inc is predominantly a B2B online gaming technology platform and casino content aggregator. The Company's proprietary studios offer high-performing, data-driven casino gaming titles from in-house brands Wild Streak, Spin, Atomic Slot Lab, Indigo Magic and Oryx Gaming. It offers a full range of games including slot games, table games, card games, video bingo, scratch card games, virtual sports, and live dealer games which are featured on the company's PAM platform and also available for use on other gaming platforms offered by third parties. Geographically, the company generates a majority of its revenue from the Netherlands and the rest from Curacao, Malta, United States, Croatia, and other regions.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.